Kornimate/medical-research-clean huggingface dataset:
pre vs post block in total knee arthroplasty (tka)

Conditions: Knee Osteoarthritis; Arthroplasty Complications; Postoperative Pain

Summary: the purpose of this project is to determine if a change in patient reported pain, nausea and vomiting after total knee arthroplasty can be observed with the substitution of a post operative adductor canal block for a preoperative adductor canal block in the current established peri-operative pain protocol and if these changes lead to a decrease in opioid consumption (in morphine equivalents).


Eligibility criteria:
inclusion criteria: 1- patients 18 or older 2 - patients undergoing primary total knee replacement at the university of miami hospital 3 - patients that have capacity to provide medical consent exclusion criteria: 1. all patients under the age of 18 2. prisoners, uncontrolled diabetics, increased risk of bleeding, pregnant women, women planning on becoming pregnant in the next year, and women who think they might be pregnant. 3. patients with prior surgery or history of infection on the joint of interest. 4. patients on steroid preoperatively. 5. inability to provide medical consent. 6. patients with a history of significant unmitigated pain in parts of their body not including the knee the procedure is to be performed or a history of pain catastrophizing (the tendency to magnify the threat value of the pain stimulus and to feel helpless in the context of pain, and by a relative inability to inhibit pain-related thoughts in anticipation of, during or following a painful event) regarding pain anywhere in the body. 7. any condition that, in the opinion of the investigator, would compromise the well-being of the patient or the study or prevent the patient from meeting or performing study requirements will exclude the participant. 8. allergy to local anesthetic or any medication used in the standard protocol for joint replacement.
quality-of-life and pain after spa treatment in elderly with osteoarthritis

Conditions: Osteoarthritis; Quality of Life; Elderly; Balneology

Summary: the aim of the study was to evaluate the short- and long-term effects of spa therapy on quality of life and pain in patients aged 65 years and older with osteoarthritis. 70 patients with osteoarthritis referred to spa treatment in south-eastern poland were enrolled in the study. spa treatment lasted 3 weeks. all the patients benefited from spa therapy. vas pain scale, the laitinen scale and whoqol-bref questionnaire were used to assess the condition of the patients. the examinations were performed three times: at the beginning of the spa treatment, after three months and one year after the first examinations.

in an interventional study design, there have been examined patients aged over 65 years with the diagnosis of osteoarthritis who were prescribed a first spa therapy course in spa resorts in south-eastern poland, between april 2016 and july 2016. patients were assessed by an experienced physicians on the first day of the spa therapy (study 1), after three months (study 2) and one year (study 3) after the completion of the spa therapy. all patients who had been enrolled to the study, were asked to fill out the appropriate questionnaires (on the first day of the spa therapy). the investigators ensured that questionnaires were properly completed, under the supervision of researcher previously trained for their application. second (study 2) and third (study 3) stages of the study were performed after three months, and one year after the first study, respectively (participants were interviewed by telephone survey). interventions spa treatment was applied during a session lasting 120 to 150 minutes a day. spa treatment lasted 3 weeks, including treatments from monday to friday (15 days of treatment). as a part of comprehensive spa treatment, all the patients benefited from kinesiotherapy, physical agent modalities (electrotherapy, phototherapy), massage and balneotherapy (peloid therapy, hydrotherapy with mineral waters, crenotherapy).

Eligibility criteria:
inclusion criteria: * age over 65 * diagnosis of osteoarthritis, * completion of 3 weeks of spa treatment * patient's consent to participate in the study exclusion criteria: * failure to complete 3-weeks spa treatment, * significant random events during follow-up * diagnosed other diseases during follow-up, * other forms of therapy implemented during follow-up, * refusal to participate in ii or iii stage of the study
evaluate effectiveness of epiduo® gel in reducing antibiotic sensitive & resistant strains of propionibacterium (p)acnes

Conditions: P Acnes Colonization

Summary: the purpose of this study is to evaluate the effectiveness of epiduo® gel in reducing antibiotic sensitive and resistant strains of p acnes in vivo.


Eligibility criteria:
inclusion criteria: * healthy adult male or female subjects 18 years of age and older, with no past or present history of any significant internal disease * subjects who: * show a high degree of fluorescence of the facial skin under a wood's lamp, indicating the presence of p acnes * have baseline p acnes count of \> 10,000 per cm2 cfu of the facial skin (forehead) * have high level resistance to erythromycin, variable resistance to clindamycin, resistance to tetracycline and variable resistance to doxycycline and minocycline exclusion criteria: * subjects who exhibit any skin disorders of an acute or chronic nature (e.g., psoriasis, eczema, etc) * subjects who have taken topical or systemic antibiotics within 4 weeks prior to baseline assessments * subjects who have used other medications which may influence skin surface p acnes levels * subjects who are unwilling to refrain from using toners, astringents or other drying agents on the face during the study
cardio-renal registry

Conditions: End Stage Renal Disease; Cardio-Renal Syndrome; Myocardial Infarction; Cerebrovascular Accident; Percutaneous Coronary Intervention; Dialysis

Summary: cardiovascular disease is the leading cause of morbidity and mortality among patients with chronic kidney disease (ckd). even after adjustment for known cardiovascular risk factors, including diabetes and hypertension, mortality risk progressively increases with worsening ckd. as glomerular filtration rate (gfr) declines the probability of developing coronary artery disease (cad) increases linearly, and patients with gfr \<60 ml/min/1.73 m2 have 2-3-fold increased cv mortality risk, relative to patients without ckd. management of cad is complicated in ckd patients due to the likelihood of comorbid conditions and potential for side effects. despite their high cardiovascular risk, acs patients with renal dysfunction are less commonly treated with guideline-based medical therapy and are less frequently referred for coronary revascularisation. this observation, referred to as the "treatment risk paradox," has been well described and may be explained by physicians' concerns regarding possible nonrenal side effects as well as renal toxicities. furthermore, patients with severe ckd have traditionally been under-represented in most large cardiovascular clinical trials. therefore, recommendations for both medical and revascularisation of cad have relied heavily on extrapolation of results from the non-ckd population. this data will add to that literature by assessing the characteristics and outcomes of patients with cad and ckd. it will also identify and characterise predictors of outcomes, improve risk stratification and diagnostic evaluation.


Eligibility criteria:
informed consent will not be sought for, as patients are automatically included onto a database that we will use for research purposes. no children will be included in this study. vulnerable adults or those unable to give consent will be included in the study as well if they are referred to the nephrology team. inclusion criteria: 1. both male and female patients ≥16 years of age will be included 2. all patients will be reviewed by the nephrology team a the rlh with renal disease. exclusion criteria: 1. patients \<16 years will not be included in this study.
phase 2 study of ngm282 in patients with primary biliary cirrhosis

Conditions: Primary Biliary Cirrhosis

Summary: the purpose of this study is to determine the safety, tolerability, and activity of ngm282 in patients with primary biliary cirrhosis.


Eligibility criteria:
inclusion criteria: * males or females, between 18 and 75 years of age, inclusive * pbc diagnosis consistent with aasld and easl guidelines * stable dose of udca exclusion criteria: * chronic liver disease of a non-pbc etiology * evidence of clinically significant hepatic decompensation
medication-related osteonecrosis of the jaw (mronj) registry

Conditions: Medication-related Osteonecrosis of the Jaw; Bisphosphonate-Associated Osteonecrosis of the Jaw

Summary: approximately 500 patients will be included in this patient registry. data collection includes demographics, clinical data of underlying disease and use of bisphosphonates, denosumab and antiangiogenic drugs , degree and extension of osteonecrosis, osteonecrosis-specific treatment, outcomes and complications within 1 year after treatment.

approximately 500 patients diagnosed with medication-related osteonecrosis of the jaw will be enrolled in the study. patients will undergo standard (routine) of care treatment, either conservative or surgical or both, and followed up during one year after the initiation of the treatment. treatment outcome (development of the condition), pain and complications will be collected and documented over the duration of the registry.

Eligibility criteria:
inclusion criteria: * age \> 18 years * newly diagnosed patients with osteonecrosis in a facial bone other than the jaw, or * newly diagnosed patients with non-exposed mronj (stage 0), or * newly diagnosed patients with exposed mronj, i.e: * current or previous treatment with antiresorptive or antiangiogenic agents. * exposed bone or bone that can be probed through an intraoral or extraoral fistula(e) in the maxillofacial region that has persisted for more than 8 weeks * no history of radiation therapy to the jaws or obvious metastatic diseases of the jaw * ability to understand the content of the patient information/ informed consent form * willingness and ability to participate in the clinical investigation according to the registry plan (rp) * signed and dated irb/ec-approved written informed consent * mental capacity to comply with post-operative regimen, evaluation and data collection exclusion criteria: * recent history of substance abuse (i. e., recreational drugs, alcohol) that would preclude reliable assessment * pregnancy or women planning to conceive within the registry period * prisoner * participation in any other medical device or medicinal product study within the previous month that could influence the results of the present registry

Keywords: bisphosphonate jaw osteonecrosis antiresorptive drugs denosumab
virtual study in achondroplasia for the us (vista)

Conditions: Achondroplasia

Summary: this is an observational study of individuals with achondroplasia in the united states. the primary study population consists of pediatric individuals treated and untreated with voxzogo™. study enrollment started in february 2023. the projected total duration of the study is approximately 5 years at minimum from start of study recruitment in february 2023, with the duration of individual prospective follow-up differing depending on the time of enrollment. the study duration may be extended based on decisions by the study sponsor. data will be collected in two formats for the primary pediatric study population: 1. participant-mediated access to electronic health records(including medical imaging, when available) which will enable retrospective and prospective collection of secondary data reflecting real-life treatment use and clinical care. . 2. primary data collection of clinical outcome assessments (coas) and questionnaire data. data will be collected in the following format for the adult cohort: - participant-mediated access to electronic health records (including medical imaging, when available) which will enable retrospective and prospective collection of secondary data reflecting real-life treatment use and clinical care. the primary study population will include approximately 150 pediatric individuals with achondroplasia regardless of their treatment status with voxzogo™. individuals may change status from untreated to treated during the prospective period of the study (or vice versa) however they will only be counted once, based on their treated status at the point of enrollment. the secondary study population will include 20 adolescent and adult participants.


Eligibility criteria:
inclusion criteria: * physician diagnosis of achondroplasia * age at time of enrollment: primary pediatric cohort: ≤13 years old secondary adolescent and adult cohort: ≥14 years old * receiving medical care in the united states * complete picnichealth's onboarding process, including signing informed consent and authorization for medical record retrieval exclusion criteria: * lack of any medical records
14-c adme (absorption, disposition, metabolism and excretion) study in man

Conditions: Healthy Subjects

Summary: this is an open-label study to determine the adme (absorption, disposition, metabolism and excretion) of 14c labeled slv337 after a single dose of an oral suspension.

the absorption, disposition, metabolism and excretion of slv337 will be investigated after a single dose of an oral suspension of 14c-slv337.

Eligibility criteria:
inclusion criteria * bmi 18 - 28 kg/m2 * sbp 90-140 * dbp 50-90 exclusion criteria * seizures, * orthostatic hypotension

Keywords: slv337 diabetes relative bioavailability adme
elderly back pain: comparing chiropractic to medical care

Conditions: Subacute Low Back Pain; Chronic Low Back Pain

Summary: the purpose of this study is to compare the clinical effectiveness of two types of chiropractic spinal manipulation to conservative medical care for patients at least 55 years old with sub-acute or chronic low back pain (lbp).

despite the high prevalence of lbp and the associated economic costs, disability, and lost productivity, and despite the development of several treatment guidelines, one of which recommends chiropractic spinal manipulation for some subgroups of patients with pack pain, the management of lbp remains controversial and highly variable across professions and geographic regions. although one recent publication describes the design of chiropractic and exercise for seniors with low back or neck pain, no published studies to our knowledge, have assessed the effectiveness of chiropractic manipulation compared to medical care for older adults with sub-acute or chronic low back pain.

Eligibility criteria:
inclusion criteria: * age 55 or older * idiopathic low back pain (lbp) of at least four weeks duration * meet the diagnostic classification of 1, 2, or 3 according to the quebec task force on spinal disorders exclusion criteria: * low back pain (lbp) not meeting quebec task force diagnostic classifications 1, 2 or 3, especially lbp associated with: frank radiculopathy, altered lower extremity reflex, dermatomal sensory deficit, progressive unilateral muscle weakness or motor loss, symptoms of cauda equina compression, and ct or mri evidence of anatomical pathology (e.g. abnormal disc, lateral or central stenosis. * co-morbid conditions or general poor health that could significantly complicate the prognosis of lbp, including pregnancy, bleeding disorders, extreme obesity, and clear evidence of narcotic or other drug abuse. * major clinical depression defined as scores greater that 29 on the beck depression inventory - second edition * bone or joint pathology that contraindicate spinal manipulative therapy of joint pathology that contraindicate spinal manipulative therapy of the arthropathies and significant osteoporosis * pacemaker, because there are safety issues with equipment used to collect data in the biomechanical testing laboratory * current or pending litigation related to current episode of lbp. * receiving disability for any health-related condition * spinal manipulative care for any reason within the past month * unwilling to postpone use of manual therapies for lbp except those provided in the study for the duration of the study period. * unable to read or verbally comprehend english.
congenital aniridia patient questionnaire

Conditions: Congenital Aniridia

Summary: congenital aniridia is a pan-ocular genetic disease characterized by a partial or complete absence of the iris, hence its name. the prevalence ranges from 1 / 40,000 to 1 / 96,000 births, but it may be underestimated. this condition combines several types of eye damage and could associate systemic manifestations, with a variable phenotype and genotype. this study aims to identify eye and systemic manifestations in congenital aniridia and to determine the patients' knowledge of their own disease through a survey prepared by ophthalmologists from the ophthalmology department of necker-enfants malades hospital, reference center in france for this pathology. the patient fills it out only once.

congenital aniridia is a pan-ocular genetic characterized by partial or complete absence of the iris, hence its name. the prevalence ranges from 1 / 40,000 to 1 / 96,000 births, but it may be underestimated. this condition combines several types of eye damage : * partial or complete absence of iris, iris abnormalities * glaucoma * cataract * corneal opacifications with neovascularization * foveal hypoplasia with nystagmus * hypoplasia of the optic nerve the signs of the disease vary from one individual to another, even within the same family. iris abnormalities and foveolar hypoplasia are the most constant signs. affected patients have a highly compromised visual prognosis in adulthood, and are very often considered visually impaired with criteria for legal blindness. congenital aniridia can also be associated with several severe systemic manifestations, including syndromic aniridia (wagr syndrome and gillespie syndrome). the major gene responsible for autosomal dominant forms of congenital aniridia is paired box gene 6 (pax6) (mim#607108) with over 500 pathogenic variants reported to date. congenital aniridia is therefore a rare, pan-ocular disease associating systemic manifestations, with a variable phenotype and genotype. this study aims to identify eye and systemic manifestations in congenital aniridia and to determine the patients' knowledge of their own disease through a survey prepared by ophthalmologists from the ophthalmology department of necker-enfants malades hospital, reference center in france for this pathology. the patient fills it out only once.

Eligibility criteria:
inclusion criteria: * any patient ≥ 18 years old with congenital aniridia and able to respond independently to the study survey, * or patients under 18 years old with congenital aniridia, whose parents can answer the study survey, * adult patients or holders of parental authority and minor patients informed and not opposed to participation in the study. exclusion criteria: - patients with neurological disorders preventing them from answering the survey, except in the case of minor patients, if the parents can answer for the patient.

Keywords: congenital aniridia patient survey patients knowledge
national heart failure registry

Conditions: Chronic Heart Failure

Summary: a prospective-retrospective observational registry of patients diagnosed with chronic heart failure in the regions of the russian federation. the study is non-interventional and does not involve any interventions in clinical practice, the choice of treatment methods (including the type of medical device used and the method of surgical intervention) and examination. a control observation group is not intended.

the study will include retrospective and prospective data of patients with an outpatient or inpatient diagnosis of chf. the duration of the observation period of an individual patient with chf is limited by the study period, or the patient's death, and includes the studied retrospective and dynamic prospective parameters. prospective data of chf (any stage and fc) subjects are planned to be included sequentially as they appear in inpatient chf centers and outpatient chf offices until 12/31/2027 inclusive and further upon extension of the study. retrospective data will be provided by chief freelance cardiologists of 33 constituent entities of the russian federation (central federal district, ural federal district, siberian federal district, far eastern federal district) (individually, according to agreement)

Eligibility criteria:
inclusion criteria: * any stage and/or any class of chf exclusion criteria: * subjects whose source records cant be obtained for the analysis
a study of sintilimab plus chemoradiation before surgery for esophageal cancer

Conditions: Esophageal Squamous Cell Carcinoma

Summary: the purpose of this study is to test the the efficacy and safety of sintilimab in combination with chemoradiation before surgery for esophageal cancer.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed esophageal squamous carcinoma * 18≤age≤75 * ecog ps is 0-1 * tanyn+m0 or t3-4nanym0 tumors * patients must have surgically resectable disease treatable by esophagectomy, as assessed by a thoracic surgeon * no prior chemotherapy,radiotherapy and immunotherapy * disease must be clinically limited to the esophagus * no esophageal perforation and no active esophageal bleeding * no interstitial pneumonia or history of interstitial pneumonia * fev1\>1.2l * adequate organ function defined at baseline as: wbc ≥3,000/ l，anc ≥1,500/ l，platelets ≥100,000/ l，hb ≥9 g/dl； calculated creatinine clearance \>40 ml/min using cockcroft-gault method: males: creatinine cl = weight (kg) x (140 - age) . (ml/min) 72 x serum creatinine (mg/dl)female：creatinine cl (ml/min) = weight (kg) x (140 - age) x 0.85 72 x serum creatinine (mg/dl)；total serum bilirubin ≤1.5 mg/dl， ast/alt ≤2.5× upper limit of normal，mean qt interval corrected for heart rate (qtc) \<470 ms calculated from 3 ecgs using frediricia's correction * able to provide written informed consent * subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up exclusion criteria: * previous treatment with chemotherapy, radiotherapy or immunotherapy * cervical esophageal cancer * esophageal perforation or active esophageal bleeding * interstitial pneumonia or history of interstitial pneumonia * patients with evidence of metastatic disease * chronic hepatitis b or c infection (e.g. hepatitis b surface ag positive or detectable viral load for hepatitis b or c). patients with prior evidence of hepatitis b or c without active infection are eligible * autoimmune diseases (such as systemic lupus erythematosus, rheumatoid rthritis, inflammatory bowel disease, autoimmune thyroid disease), but allow the following diseases to enter the next stage of screening: type i diabetes, skin diseases without systemic treatment (such as vitiligo, psoriasis) * 14 days before the first dose, the patient had an active infection that required systemic treatment * inability to understand or may not comply with test requirements